Please provide your email address to receive an email when new articles are posted on . The FDA approved a third-generation PCSK9 inhibitor to reduce cholesterol in certain high-risk patients. The ...
A new study has revealed that neural inhibition and balanced neural activity in a specific area of the brain is required for recognition memory. The findings could help provide better understanding of ...
This discussion has been edited for length and clarity. Three clinicians explore the headline-making evidence from the monarchE and NATALEE trials presented at the 2025 ESMO Congress. Laura A. Huppert ...
Mistakes, whether spoken or promised, are universal. The feeling of putting our foot in our mouth arises from a key executive function that our brain controls: stopping ourselves. However, the ...
Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...
The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease risk. By Gina Kolata Merck, the company that introduced statins to the ...
Novartis has scored the FDA’s approval for a second BTK inhibitor that’s for a non-cancer indication, teeing off a potential competition with Sanofi down the line. The FDA has blessed Novartis’ ...
From Santiago Ramón y Cajal’s hand came branches and whorls, spines and webs. Now-famous drawings by the neuroanatomist in the late 19th and early 20th centuries showed, for the first time, the ...
A meta-analysis showed no significant differences between JAK inhibitor use and TNF antagonist use in terms of the risk for serious infections or malignant neoplasms in patients with immune-mediated ...
Please provide your email address to receive an email when new articles are posted on . TL1A inhibitors have shown both anti-inflammatory and anti-fibrotic activity in IBD. This class of drugs offers ...
Rilzabrutinib, a BTK inhibitor, is approved for ITP, showing significant efficacy in improving platelet response and reducing bleeding symptoms. The LUNA 3 study demonstrated rilzabrutinib's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback